Overview

A Study of Viracept in HIV-Positive Women

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.

Phase:

Phase 2

Details

Lead Sponsor:

Agouron Pharmaceuticals

Treatments:

Nelfinavir